熱門資訊> 正文
Solid Biosciences将开始在美国和加拿大测试SGT-501
2025-07-09 21:36
- Solid Biosciences (NASDAQ:SLDB) said that the U.S. FDA and Health Canada has approved its gene therapy, SGT-501,for the treatment of heart disease caused by genetic disorder.
- The company expects to initiate a first-stage trial to evaluate SGT-501 as a treatment of the disorder, called catecholaminergic polymorphic ventricular tachycardia, in the fourth quarter of 2025.
More on Solid Biosciences
- Seeking Alpha’s Quant Rating on Solid Biosciences
- Historical earnings data for Solid Biosciences
- Financial information for Solid Biosciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
